Hybrigenics hires head of corporate and business development

William Vickery joins firm from ExonHit

Hybrigenics, a French bio-pharmaceutical group with a focus on research and development of new cancer treatments and a fully-owned subsidiary specialised in protein interactions services, has appointed William Vickery to the newly created position of head of corporate and business development.

Vickery was for five years senior director of business development at ExonHit.

Prior to joining ExonHit Therapeutics in 2006 and since 2003, he was business development director of Roche Pharmaceuticals in the US, where he was responsible for out-licensing and divestiture of Roche-developed assets.

‘I am very excited about joining Hybrigenics and look forward to helping the company establish strong partnerships to develop breakthrough therapeutics to treat cancers and other diseases,’ said Vickery.

You may also like

Research & Development

Hybrigenics and Servier sign three-year research deal

Will study deubiquitinating enzymes (DUBs) applied to a number of therapeutic areas
Ingredients

Hybrigenics develops new oral formulations of inecalcitol

New capsules are more concentrated in inecalcitol and contain a fixed 2mg amount that will be more convenient, with a maximum of two small capsules to swallow, which also favours compliance
Ingredients

Hybrigenics improves inecalcitol synthesis

French firm makes patent application for high-yield inecalcitol production
Manufacturing

Anxine responds to rising demand for integrated turnkey packaging solutions

Anxine has observed that more customers are moving away from purchasing individual machines and are instead choosing complete one-stop turnkey solutions that are easier to plan, manage, and put into operation
Pharmaceutical

MHRA approves every-four-week dosing regimen for Chiesi's Elfabrio in stable adult Fabry disease patients

The firm has received MHRA approval for an additional 2 mg/kg every-four-week dosing regimen for pegunigalsidase alfa, halving the number of annual infusions required for eligible adult Fabry disease patients from 26 to 13
Regulatory

How the QA and QP Talent Market Is Changing in Pharma: Insights from Compliance Unlocked Podcast

Recruiting and retaining experienced quality and regulatory professionals has become significantly more complex for pharmaceutical and biotech companies
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Rice-ing to the occasion: how plant-based excipients are gaining ground in pharmaceutical manufacturing

As clean-label expectations migrate from health foods into pharmaceutical supply chains, natural ingredient supplier RIBUS says that rice-based excipients are becoming a credible alternative to synthetic standards
Subscribe now